SCHEMBL6292345

SCHEMBL6292345

CCCC1=C(C#N)C(c2ccccc2[N+](=O)[O-])c2c[nH]nc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CUL4A Q13619 1/20 0.47
MAPT P10636 3/20 0.40
KLK7 P49862 1/20 0.40
KMT2A Q03164 4/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
CACNA1F O60840 3/20 0.38
CACNA1D Q01668 3/20 0.38
CACNA1S Q13698 3/20 0.38
CACNA1C Q13936 3/20 0.38
HSD17B10 Q99714 3/20 0.38
ABCC4 O15439 2/20 0.38
ABCB11 O95342 2/20 0.38
LMNA P02545 2/20 0.38
CYP1A2 P05177 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292198 0.92 CUL4A (0.49) CUL4AMAPTKLK7KMT2AKDM4E
SCHEMBL6293447 0.91 CUL4A (0.38) CUL4AMAPTKLK7KMT2AKDM4E
SCHEMBL6297468 0.91 CUL4A (0.38) CUL4AMAPTKLK7KMT2AKDM4E
SCHEMBL6297245 0.85 CACNA1D (0.41) CUL4AMAPTKMT2AKDM4EALDH1A1
SCHEMBL6293389 0.85 NR3C2 (0.34) CUL4AMAPTKDM4EALDH1A1TDP1
SCHEMBL6296757 0.83 ALDH1A1 (0.43) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL6297368 0.83 HSD17B10 (0.36) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL6292239 0.82 NR3C2 (0.40) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL6292466 0.82 ALDH1A1 (0.40) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL6297275 0.82 CDK1 (0.40) MAPTKMT2AKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB CUL4A 3202/4885MAPT 96/4885KLK7 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.